Abcam A.I CyberSecurity Scoring
27/02/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Abcam in 2026.
No incidents recorded for Abcam in 2026.
No incidents recorded for Abcam in 2026.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Latest updates, reports, and threat intel affecting the global network.
The last 12 months (to October 16, 2024) has seen the sale of a number of Cambridge's life science and technology companies, the majority...
Cambridge-based cyber security AI innovator Darktrace is being sold to Thoma Bravo in the US for £5.315 billion. A deal was mooted last year...
Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.
A security vulnerability has been detected in Rizwan17 inventory-management-system up to bfe78a330d01bb26b9daec5dc9ecd5c77900e03f. This affects an unknown part of the file includes/invoice_bill.php of the component Invoice Generation. Such manipulation of the argument order_date/invoice_no leads to missing authentication. It is possible to launch the attack remotely. The exploit has been disclosed publicly and may be used. This product takes the approach of rolling releases to provide continious delivery. Therefore, version details for affected and updated releases are not available. The project was informed of the problem early through an issue report but has not responded yet.
A weakness has been identified in Rizwan17 inventory-management-system up to bfe78a330d01bb26b9daec5dc9ecd5c77900e03f. Affected by this issue is some unknown functionality of the file includes/DBOperation.php of the component List Handler. This manipulation of the argument category_name/brand_name/product_name causes cross site scripting. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. This product is using a rolling release to provide continious delivery. Therefore, no version details for affected nor updated releases are available. The project was informed of the problem early through an issue report but has not responded yet.
Authentication Bypass via Hardcoded Master Verification Code vulnerability in Siam Ordering (siam-server) 1.0.0 allows remote unauthenticated attackers to log in as any user, merchant, or administrator.
The Bluetooth Classic (BR/EDR) L2CAP receive handler bt_l2cap_br_recv() in subsys/bluetooth/host/classic/l2cap_br.c dispatched inbound data PDUs based only on the destination channel ID, without checking that the target channel had reached the BT_L2CAP_CONNECTED state. A dynamic channel is assigned its RX CID and added to the connection's channel list while still in BT_L2CAP_CONNECTING (and later BT_L2CAP_CONFIG) — before configuration completes and, for PSMs that require security, before the peer is authenticated (l2cap_br_conn_req()). Because the channel is already findable by bt_l2cap_br_lookup_rx_cid() during this window, a remote peer within radio range can send a data PDU addressed to that CID and have it processed on a not-yet-established channel. The dispatch keys off channel fields (BR_CHAN(chan)->rx.mode, rx.mps) that are only initialized during configuration by l2cap_br_conf(); since channel objects are pooled and bt_l2cap_br_chan_del() does not reset rx.mode or the reassembly buffer _sdu, a reused channel can carry stale state into the CONNECTING window and route the frame into the retransmission/flow-control path (bt_l2cap_br_ret_fc_recv()) with stale parameters and a possibly stale _sdu pointer. The impact is delivery of attacker data to upper-layer protocol handlers on a half-open (and possibly unauthenticated) channel, plus operation on stale or partially initialized channel state on reused channel objects — leading to channel/link teardown (denial of service) and, in the stale-_sdu case, a dangling-pointer condition. The fix adds an explicit BR_CHAN(chan)->state < BT_L2CAP_CONNECTED guard that drops any data received before the channel is fully connected.
Pandora contains a path traversal vulnerability in its archive extraction worker. When processing a specially crafted archive or disk image, attacker-controlled file paths could be used without ensuring that the resulting destination remained within the intended extraction directory. An attacker able to submit a malicious file for analysis could use path traversal sequences or crafted paths to cause extracted content to be written outside the designated extraction directory, potentially overwriting files accessible to the Pandora worker process. Successful exploitation could result in unauthorized modification of application or system files, denial of service, and potentially further compromise depending on the permissions of the Pandora process and the files that can be overwritten. The vulnerability is addressed by resolving each extraction destination path before writing and verifying that it remains below the expected extraction directory. Extraction attempts resolving outside this directory are rejected and reported as path traversal attempts.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.